Irshad Hasan, MD
Family Medicine · Rossford, OHNPI 1891771184
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 533 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,316 and has fallen 87.5% since, to $289 in 2025. Among family medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 533 payments — averaging $14.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$968
- Novo Nordisk$829
- Pfizer$649
- Johnson & Johnson$569
- AstraZeneca$489
- Sanofi-aventis U.S. LLC$402
- plus $4K from 33 others
What the payments were for
- Food & beverage$7,678100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,684 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 521 | $184,306 |
| OzempicSemaglutide | 72 | $70,049 |
| JardianceEmpagliflozin | 112 | $50,843 |
| FarxigaDapagliflozin Propanediol | 84 | $48,428 |
| XareltoRivaroxaban | 124 | $44,925 |
| XifaxanRifaximin | 33 | $43,586 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $42,355 |
| TrulicityDulaglutide | 40 | $39,320 |
| JanuviaSitagliptin Phosphate | 74 | $38,784 |
| MyrbetriqMirabegron | 64 | $31,563 |
| EntrestoSacubitril/Valsartan | 32 | $18,212 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 52 | $15,289 |
| GemtesaVibegron | 33 | $13,096 |
| Atorvastatin Calcium | 1,120 | $12,632 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 133 | $12,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $649 | $192,332548 claims |
| Novo NordiskOzempic | $829 | $70,04972 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $180 | $59,858118 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $489 | $59,45998 claims |
| Boehringer IngelheimJardiance | $323 | $50,843112 claims |
| Johnson & JohnsonXarelto | $569 | $44,925124 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $137 | $43,58633 claims |
| Lilly USA, LLCTrulicity | $202 | $39,32040 claims |
| MerckJanuvia | $247 | $38,78474 claims |
| Astellas Pharma US IncMyrbetriq | $149 | $31,56364 claims |
| NovartisEntresto | $268 | $18,21232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Rossford
- Robert SchmidtRossford$27K
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
- Tricia BedrickCuyahoga Falls$259K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.